



CARsgen Therapeutics (HKEX: 02171)

April 2025

Making Cancer Curable

Disclaimer



THIS DOCUMENT IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT INTENDED TO BE, AND SHALL NOT BE CONSTRUED AS, AN OFFER, INDUCEMENT, INVITATION, SOLICITATION, COMMITMENT OR ADVERTISEMENT WITH RESPECT TO THE PURCHASE, SUBSCRIPTION OR SALE OF ANY SECURITY AND NO PART OF IT SHALL FORM THE BASIS OF, OR BE RELIED UPON IN CONNECTION WITH, ANY CONTRACT OR COMMITMENT WHATSOEVER.

The recipient agrees to keep the contents of the document confidential and must not reproduce or distribute the document, in whole or in part, to any person in any manner whatsoever, without the prior written consent of the Company.

Unless otherwise indicated, the information used in preparing the document was prepared by the Company or from public sources and has not been independently verified by any person. This document is for discussion purposes only and has not been prepared with a view toward public disclosure under applicable securities laws or otherwise. The contents of this document are subject to corrections or changes at any time without further notice and will not be updated to reflect material developments which may occur after the date of this document. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of such information and nothing contained herein is, or shall be relied upon as, a representation, whether as to the past, the present or the future. None of the Company, its affiliates, directors, officers, employees, advisers, agents or representatives or any other person shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of the contents of this document or otherwise arising connection therewith.

This document is not intended to provide the basis for evaluating and should not be considered a recommendation with respect to, any transaction or other matter. Any analyses included herein are not and do not purport to be appraisals of the assets or business of the Company or any of its subsidiaries or affiliates. Nothing in this document should be construed as regulatory, valuation, legal, tax, accounting or investment advice. Before you enter into any transaction, you should ensure that you will be responsible for conducting your own due diligence investigation with respect to the Company and fully understand the potential risks and rewards of that transaction and you should consult with such advisers as you deem necessary to assist you in making these determinations, including, but not limited to, your accountants, investment advisors and legal and/or tax experts. Any decision to purchase securities of the Company in any public or private offering should be made solely on the basis of the prospectus and/or international offering circular to be prepared by the Company in relation to any such contemplated offering together with any supplementary pricing information. This document contains no information or material which may result in it being deemed (1) to be a prospectus within the meaning of section 2(1) Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong) (the "Companies Ordinance"), or an advertisement in relation to a prospectus or proposed prospectus or extract from or abridged version of a prospectus within the meaning of section 2(3) of the Laws of Hong Kong) (the "Securities and Futures Ordinance") or (2) in Hong Kong to have effected an offer to the public without compliance with the laws of Hong Kong or being able to invoke any exemption available under the laws of Hong Kong, and is subject to material change without notice.

This document contains forward-looking statements that express the Company's current views, projections, beliefs and expectations with respect to future events as of the respective dates indicated herein. Such forward-looking statements are based on a number of assumptions and factors beyond the Company's control. As a result, they are subject to significant risks and uncertainties and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this document might not occur. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this document.

This document is not an offer for sale of or a solicitation of an offer to buy securities in the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent registration or an available exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act").

By reading this document and attending the presentation, you agree to be bound by the foregoing restrictions, and you shall be deemed to have represented to us that you (and any customers you represent) are either (a) a qualified institutional buyer (as defined in Rule 144A under the U.S. Securities Act) or (b) outside the United States (within the meaning of Regulation S under the U.S. Securities Act). You also represent that you (and any customers you represent) are "professional investors" described in Part I of Schedule 1 to the Securities and Futures Ordinance and any subsidiary legislation thereunder (including but not limited to the Securities and Futures (Professional Investor) Rules (Chapter 571D of the Laws of Hong Kong)).

CARSGEN THERAPEUTICS Confidential Copyrights reserved by CARsgen

We Develop Innovative and Differentiated Cell Therapies to Make Cancer and Other Diseases Curable





Global Reach with Integrated R&D and Manufacturing Capabilities Complemented with Synergistic Partnership









Partnerships

moderna

(NASDAQ: MRNA)

Evaluate satri-cel in combination with an mRNA Cancer Vaccine




inno.N (KOSDAQ: 195940)

License of zevor-cel and CT032 in the Republic of Korea

Continuous Innovation and Technology Advancement to Tackle the Major Challenges with CAR-T therapies Since 2014





Enabling Technologies



K 7	LADAR®
К Л	(precise targeting)

 \mathcal{O}

Lymphodepletion (FNC regimen)

Binder (humanized/fully-human antibodies against ~20 targets)

	Product Candidate ¹	Target	Indication	Pre-clinical	Phase I	Phase II/III ²	BLA NDA
	Zevor-cel (CT053) ³	BCMA	R/R MM R/R MM	LUMMICAR 1 (China) LUMMICAR 2 (US, Canada)			launched
Autorogous CAR-T	Satri-cel (CT041)	Claudin18.2	GC/GEJ GC/PC PC (adjuvant) GC/GEJ, PC, etc. GC/GEJ (adjuvant)	ST-01 (China) ST-02 (US, Canada) ST-05 (China) IIT (China) IIT (China)			
AU	СТ071	GPRC5D	R/R MM, R/R pPCL R/R MM, R/R PCL NDMM	(US) IIT (China) IIT (China)			
	CT011	GPC3	HCC (adjuvant)	(China)			
	CT0590⁴	BCMA	R/R MM, R/R PCL	IIT (China)			
•	СТ059Х	BCMA	R/R MM, R/R PCL	IIT (China)			
Allogeneic CAR-T	KJ-C2219	CD19/CD20	B-cell malignancies SLE, SSc	IIT (China) IIT (China)			
og All	KJ-C2320	CD38	AML	IIT (China)			
	KJ-C2114	Undisclosed	Solid tumors				
	KJ-C2526	NKG2DL	AML, other malignancies, senescence				

Competitive Product Pipeline with Global Rights

¹ All product candidates are self-developed with global rights

² Phase II trials of some indications are pivotal studies

³ Core Product Candidate. Commercial rights in mainland China have been granted to Huadong Medicine (SZ: 000963). Rights in the South Korean market have been licensed out to HK Inno.N (KOSDAQ: 195940) ⁴ CT0590 enrollment finished

CARSGEN THERAPEUTICS Confidential Copyrights reserved by CARsgen

ie (SZ: junction cancer; PC: pancreatic cancer; HCC: hepatocellular carcinoma; R/R pPCL: relapsed/refractory primary plasma cell leukemia; NDMM: newly diagnosed multiple myeloma; SLE: systemic lupus erythematosus; SSc: systemic sclerosis; AML: acute myeloid leukemia

for hematologic malignancies

for solid tumors for autoimmune diseases

R/R MM: relapsed / refractory multiple myeloma; GC: gastric cancer; GEJ: gastroesophageal



CART Production Area

Autologous CAR-T Against Hematologic Malignancies



Zevor-cel: Differentiated Fully-human BCMA CAR-T for R/R MM (Approved in China)

 \Diamond



Zevor-cel Highlights

- Optimized scFv
- Enhanced binding affinity
- High stability
- Enhanced anti-tumor activity
- Excellent safety profile
- Co-stimulatory domain: 4-1BB
- Low immunogenicity
- Designations: RMAT (FDA), Orphan Drug (FDA)
- NDA approved by China NMPA (February 23, 2024)


1. Chen W, et al. EHA 2024. 2024 Jun; Oral presentation S209

China Pivotal Phase II (LUMMICAR-1) ¹ N=102					
Follow-up, median (range), Month	20.3 (0.4-27)				
ISS stage III, No. (%)	39 (38.2%)				
High risk Cytogenetic, No. (%)	61 (59.8%)				
EMD+ , No. (%)	11 (10.8%)				
Prior lines of therapies, median (range)	4 (3-15)				
Double-class refractory*, No. (%)	91 (89.2%)				
Triple-class refractory**, No. (%)	23 (22.5%)				
ORR, No. (%)	94 (92.2%)				
CR/sCR, No. (%)	73 (71.6%)				
≥VGPR, No. (%)	93 (91.2%)				
mDoR, Month	Not mature				
mPFS, Month	Not mature				
MRD negative***, No. (%)	73 (100%)				
≥Grade 3 CRS, No. (%)	7 (6.9%)				
≥Grade 3 NT, No. (%)	0				
Treatment related death, No.	1				


*Double-class refractory: Refractory to a proteasome inhibitor and immunomodulatory drug **Triple-class refractory: Refractory to a proteasome inhibitor, immunomodulatory drug and anti-CD38 antibody ***In the patients achieved CR/sCR

Zevor-cel: Outstanding Efficacy and Manageable Safety









Long-term survival with deep response

It has been reported that ISS-III and high risk cytogenetics could impact the efficacy of BCMA CAR-T. Although, zevor-cel treated a high percentage of patients at ISS III stage or high risk cytogenetics in pivotal phase II, it showed competitive efficacy (left figures).

Overall Superior efficacy

٠

- IIT¹: ORR of 87.5%, sCR/CR rate of 79.2%.
- Phase I²: 2-year OS rate of 100%, 3-year OS rate of 92.9%.
- Pivotal phase II^{3,4}: ORR of 92.2%, predicted **30-month OS rate** of **87.7%** (in patients who achieved CR/sCR).

Higher safety, lower incidence of SAE

- In IIT, Phase I, and Phase II studies
- ≥Grade 3 CRS incidence: 0%, 0%,
 6.9%, respectively.
- ≥Grade 3 neurotoxicity incidence: 4.2%, 0%, 0%, respectively.
- Treatment-related death: 0%, 0%, 1%, respectively.
- ◆ Low incidence of ≥Grade 3 infections or prolonged hematologic toxicity
- Low incidence of \geq Grade 3 infections.
- Significantly low incidence of ≥Grade 3 prolonged (>30 days) cytopenia.

2. Fu C, et. al. ASH 2023. 2023 Dec; Poster #4845


4. Chen W, et al. [poster]. 2024 ASH. 2024 Dec; Poster 4762

^{1.} Yang M, et. al. *Haematologica*. 2022 Aug 1;107(8):1960-1965

^{3.} Chen W, et al. EHA 2024. 2024 Jun; Oral presentation S209

CT071: Differentiated GPRC5D CAR-T with CARcelerate[®] Platform





CT071: Baseline Characteristics



Patient Characteristics	0.1×10 ⁶ cells/kg (n=8)	0.3×10 ⁶ cells/kg (n=9)	All Patients (n=17)
R-ISS disease stage, No. (%)			
II	4 (50.0)	8 (88.9)	12 (70.6)
III	4 (50.0)	0	4 (23.5)
ECOG PS, No. (%)			
1	4 (50.0)	5 (55.6)	9 (52.9)
2	1 (12.5)	0	1 (5.9)
Extramedullary Disease a, No. (%)	2 (25.0)	2 (22.2)	4 (23.5)
High-risk cytogenetics, No. (%)	6 (75.0)	6 (66.7)	12 (70.6)
Prior Lines of Therapy, median (range)	4 (1, 12)	5 (3, 7)	5 (1, 12)
Prior CAR T, No. (%)	2 (25.0)	2 (22.2)	4 (23.5)
Prior ASCT, No. (%)	2 (25.0)	7 (77.8)	9 (52.9)
Double-class Refractory ^b , No. (%)	7 (87.5)	9 (100)	16 (94.1)
Triple-class Refractory °, No. (%)	4 (50.0)	7 (77.8)	11 (64.7)

Note, a) defined as soft tissue or paramedullary plasmacytomas; b) Double-class: one or more proteasome inhibitor, and one or more immunomodulatory drug; c) Triple-class: one or more proteasome inhibitor, one or more immunomodulatory drug, and one or more anti-CD38 antibody.

Abbreviations: R-ISS, Revised International Staging System; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ASCT, Autologous Stem Cell Transplantation.

*Cut-off date: June 21, 2024 1. Du J, et al. 2024 ASH. 2024 Dec; Poster 3451

CARSGEN THERAPEUTICS Confidential Copyrights reserved by CARsgen

CT071: Early and Deep Responses with Promising Safety Profile



	0.1×10 ⁶ cells/kg (n=8)	0.3×10 ⁶ cells/kg (n=9)	All Patients (n=17)
ORR, No. (%)	8 (100)	8 (88.9)	16 (94.1)
CR/sCR rate, No. (%)	5 (62.5)	4 (44.4)	9 (52.9)
VGPR or better rate, No. (%)	5 (62.5)	5 (55.6)	10 (58.8)
Time to CR or better, Median (range), Month	1 (1.0, 1.1)	1.9 (1.0, 4.3)	1 (1.0, 4.3)
MRD Negativity (<10 ⁻⁶) in BM, No. (%)	8 (100)	7 (77.8)	15 (88.2)
MRD negativity (<10 ⁻⁶) with CR/sCR subjects*, No. (%)	5 (100)	4 (100)	9 (100)
CRS, No. (%)	6 (75.0)	5 (55.6)	11 (64.7)
Grade 1, No. (%)	5 (62.5)	3 (33.3)	8 (47.1)
Grade 2, No. (%)	1 (12.5)	2 (22.2)	3 (17.6)
ICANS, No. (%)	0	0	0
Onychomadesis, No. (%)	4 (50.0)	0	4 (23.5)
Skin rash, No. (%)	0	1 (11.1)	1 (5.9)
AE leading to death, No. (%)	0	0	0

Abbreviations: CI, Confidence Interval; CR, Complete Response; DOR, Duration of Response; MRD, Minimal Residual Disease; NA,


Not Applicable; ORR, Objective Response Rate; PR, Partial Response; sCR, Stringent Complete Response; SD, Stable Disease;

VGPR, Very Good Partial Response; TRAE, Treatment-related Adverse Event; SAE, Serious Adverse Event; CRS, Cytokine Release

Syndrome; ICANS, Immune Effector Cell-associated Neurologic Syndrome.

*Percentages were calculated based on CR/sCR patients (n=9) **LARSGEN THERAPEUTICS** Confidential Copyrights reserved by CARsgen *Cut-off date: June 21, 2024 1. Du J, et al. 2024 ASH. 2024 Dec; Poster 3451

CT071: Rapid and Durable Responses



Note:

* Previous exposure to BCMA CAR-T.

Previous exposure to BCMA/CD19 CAR-T.

Seven patients achieved CR or better at week
4.

- All 4 patients with previous exposure to BCMA or BCMA/CD19 CAR-T responded (2 sCR and 2 PR).
- One patient with SD demonstrated ongoing tumor shrinkage of a large EMD (125 mm×99 mm at baseline) with 38.2% decrease at week 26, along with 93.0% decrease in serum M protein from baseline.

12


Autologous CAR-T Against Solid Tumors

100



Unmet Medical Needs in Solid Tumors, Including Gastric and Pancreatic Cancers






1. International Agency for Research on Cancer. Population factsheets. 2022

2. Shitara K, et al. Lancet Oncol. 2018 Nov;19(11):1437-1448

CARsgen Proprietary Claudin18.2 IHC Test



Claudin18.2 IHC test kit with high sensitivity




Satri-cel (CT041): Global First-in-Class CAR-T for Claudin18.2-Positive Solid Tumors



Product 🔗	Designations	E	Clinical Development Plan		
	• RMAT (FDA)				
 Optimized scFv¹ High binding affinity 	• Orphan Drug (FDA)		 GC (3L+) confirmatory Phase II trial in China: Enrollment completed; positive 		
 High stability 	Breakthrough Therapy (NMPA)		 topline results; plan to submit the NDA in H1, 2025 PC adjuvant therapy Phase I trial in China 		
 Innovative ENC. (EC + low-dose Nab- 	Collaboration		 Ongoing GC adjuvant therapy IIT in China: Ongoing 		
Innovative FNC (FC + low-dose Nab- Paclitaxel) preconditioning regimen to enhance penetration and anti-tumor effect of CAR-T cells	CARsgen and Moderna, Inc. (Nasdaq: MRNA) have initiated a collaboration agreement to investigate satri-cel in combination with Moderna's investigational Claudin18.2 mRNA cancer vaccine		Expansion of clinical development in • earlier lines of therapy • additional Claudin18.2 positive cancers		

Breakthrough Efficacy of Satri-cel in Later-Line Therapy for GC/GEJ





CARSGEN THERAPEUTICS Confidential Copyrights reserved by CARsgen

Satri-cel: Clinical Data from China and the United States



	China investigator-initiated trial (NCT03874897) ^{1,2}	Phase Ib/II in China (NCT04581473) ³	Phase 1b in the US (NCT04404595)⁴		
Sample size, No.	51 GC/GEJ*	14 GC/GEJ	7 GC/GEJ	12 PC	
Median follow-up, Month	32.4*	32.4* 8.8			
ORR	54.9%*	57.1%	42.9%	16.7%	
mPFS, Month	5.8**	5.6	5.7	2.7	
mDoR, Month	6.4*	Not reported	6.9	3.4	
mOS, Month	9.0**	10.8	8.9	8.9	
≥Grade 3 CRS, No.	0	1***	0	2	
≥Grade 3 ICANS, No.	0	0	0		
Treatment related death, No.	0	0	0		

*51 GC/GEJ patients with target lesions at baseline received satri-cel monotherapy.

**59 GC/GEJ patients received satri-cel monotherapy.

***One patient was related to the investigational disease (lung metastasis of GC) and fully recovered after corticosteroids treatment.

2. Qi C, et al. Nat Med (2024). https://doi.org/10.1038/s41591-024-03037-z2


CARSGEN THERAPEUTICS Confidential Copyrights reserved by CARsgen

4. Botta G, et. al. ASCO GI 2024. 2024 Jan; Abstract #356

Satri-cel: Extension to GC/PC Earlier Line Treatment



Promising great clinical value in earlier line / earlier disease stage and providing better chances of cure for a much broader patient population



CT041 as 1L Consolidation Delivered 100% Response Rate



No.	Age/Gender	BOR of 1 st line	BOR of CT041	TTR
1	50/F	SD	PR	W4
2	55/F	PR	PR	W4
3	30/F	SD	PR	W4
4	48/M	SD	NN	No target lesion
5	53/F	NE (intolerable to chemo, myelosuppression)	PR	W4

CT041 Efficacy Highlights

- ORR 100% in 4 patients with target lesions, TTR (Time-To-Response) Week 4
- 1 NN patient remained stable **beyond 15 months**
- 2 pts subsequently underwent surgical resection after satri-cel infusion, and remain alive until now.






Case 2 Case 1 **1L Treatment 1L Treatment** Regimen: POS regimen (6 cycles) + S-1/Paclitaxel/TNF Regimen: SOX regimen (4 cycles) intraperitoneal perfusion (4 cycles) • **BOR** : PR 1L BOR : SD Peritoneal disease 1st CT041 infusion Ovary recurrence 1st CT041 infusion 1L Treatment Bilateral adnexectomy progression (Best response: PR) 1L Treatment Feb 2023 Dec 2021 Jul 2021 Aug 2022 Dec 2023 Dec 2021 Nov 2020 D2 Gastrectomy + Omentectomy 3rd CT041 infusion 2nd CT041 infusion 2nd CT041 infusion Sep 2022 Sep 2023 Jun 2022 May 2023 **OS: 36.0+ months (last FU: Dec2024) OS: 39.0+ months (last FU: Mar2025)**

CARSGEN THERAPEUTICS Confidential Copyrights reserved by CARsgen

Liver Cancer: The Third Leading Cause of Cancer Mortality Worldwide





1. International Agency for Research on Cancer. Population factsheets. 2022

2. Lin L, et al. Liver Cancer. 2020 Sep;9(5):563-582

3. 2022 American Cancer Society medical information

4. Zheng R, et al. Chinese Journal of Cancer Research, 2018 Dec;30(6):571-579

CT011: First-in-class CAR-T in Hepatocellular Carcinoma with PoC Clinical Results



GPC3: high expression and specificity

 Overexpression in hepatocellular carcinomas (HCC), and is associated with poor disease prognosis

> CARsgen's GPC3 IHC test kit Expression* in HCC: 70.7%

 overexpressed in other cancer types, e.g. >60% of lung squamous cell carcinoma (SCC)

CT011

Product

✓ an autologous GPC3 CAR-T product

Clinical Development

•

- Phase I trial Completed
- Phase I trial for stage IIIa HCC at high risk of recurrence after surgical resection Ongoing

*CARsgen internal data


CAR-T in Combination with Small Molecules Against HCC: First publication in *Molecular Therapy*



> Mol Ther. 2019 Aug 7;27(8):1483-1494. doi: 10.1016/j.ymthe.2019.04.020. Epub 2019 Apr 29.

Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma

Xiuqi Wu¹, Hong Luo², Bizhi Shi¹, Shengmeng Di¹, Ruixin Sun¹, Jingwen Su¹, Ying Liu¹, Hua Li¹, Hua Jiang³, Zonghai Li⁴





Andras Heczey¹ https://doi.org/10.1016/j.ymthe.2019.07.008

Frontiers | Frontiers in Immunology

Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report

TYPE Case Report PUBLISHED 17 August 2022 DOI 10.3389/fimmu.2022.963031

As of Dec 2021 (last follow-up at publication)

 CR status has been over 24 months and continues



(Photo taken in Jun 2023)

1. Wu X, Mol Ther. 2019 Aug 7;27(8):1483-1494

CAR-T in Combination with Local Therapy Against HCC: Cover Story in *Cancer Communications,* Highlighting Two Cases of Disease-free Survival over 7 Years





LETTER TO THE EDITOR 👌 Open Access 🐵 🖲 🕏

Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy

Yaoping Shi, Donghua Shi, Jiachang Chi, Dan Cui, Xiaoyin Tang, Yan Lin, Siying Wang. Zonghai Li 🕿 Haojie Jin 🕿 Bo Zhai 🗙

First published: 21 July 2023 | https://doi.org/10.1002/cac2.12472



 54-year-old male with lbstage HCC


WILEY

CANCER

UNIT N

🤘 🍥


- Multifocal lesions in the liver, IVCTT, and retroperitoneal lymphatic metastasis;
- Previously treated with surgical resection, TACE and MWA, GKRS



Patients stayed tumor free till latest follow-up on Sep 4th, 2023

Next-Gen CAR-T Development: Tackling Key Challenges in Solid Tumors





CT041-derived Armored CAR-T demonstrates enhanced therapeutic efficacy

Proprietary CAR-NKG2DL T cells achieve 100% clearance in HCC

Allogeneic CAR-T Platforms and Pipeline Products



Existing Efficacy Gap between Allogeneic CAR-T and Autologous CAR-T



		Autologous BCMA CAR-T		
Treatment and outcomes	ALLO-715	P-BCMA-	cilta-cel	
	3.2 x10 ⁸ cells, N=24 ¹	All Arm**: 0.25-6 x10 ⁶ cells/kg, N=72	Arm C**:2 x10 ⁶ cells/kg N=23	0.5-1 x10 ⁶ cells/kg, N=97 ³
Enrolled	48	72	23 (including 2 retreatment)	113
Days to treatment initiation*	5	1	1	32
Required bridging therapy	0%	0%	0%	75%
ORR (mITT)	71%	54%	91%	98%
CR/sCR rate (mITT)	25%	11%	22%	80%
≥VGPR rate (mITT)	71%	33%	48%	95%
mDoR	8.3 months	7.7 months***	Not reported	Not reached****

*For ALLO-715, time is calculated from enrollment to lymphodepletion; for P-BCMA-ALLO1, time is calculated from enrollment to the start of study treatment.

**Four arms in total, Arm C (cy 750 mg/m²/day +Flu 30 mg/m²/day) P-BCMA-ALLO1 Dose 2 × 10⁶ and Arm B (cy 1000 mg/m²/day +Flu 30 mg/m²/day) P-BCMA-ALLO1 Dose 2 × 10⁶, Arm S (cy 300 mg/m²/day +Flu 30 mg/m²/day) P-BCMA-ALLO1 Dose 2 × 10⁶.

***The median duration of response (DoR) was 232 days for study Arms A and B – the cohorts with six or more months of follow-up at the time of data cut-off.

****Based on a median duration of follow-up of 18 months, mDOR=21.8 months.

1. Allogene Therapeutics. 2021. ASH 2021 Presentation. Accessed Nov 5, 2024

2. Poseida website news releases of phase 1 early results; Poseida Therapeutics. 2024. International Myeloma Society (IMS) 21st Annual Meeting and Exposition

3. ciltacabtagene autoleucel [Prescribing Information]. Janssen Biotech

Relatively Limited Expansion of Allogeneic CAR-T in Patients



- In allogeneic CAR-T, donor T cells will be recognized and rapidly eliminated by the host immune system (HvGR), which impacts CAR-T cell survival and results in limited expansion.
- Compared to autologous CAR-T, in vivo persistence of allogeneic CAR-T is significantly reduced.

Autologous and Allogeneic BCMA CAR-T in Multiple Myeloma							
	Allogeneic CAR-T	Autologous CAR-T					
	ALLO-715	cilta-cel	zevor-cel				
	UNIVERSAL Phase I ^{1*}	CARTITUDE-1 ²	LUMMICAR-1 Phase 1 ³				
Median C _{max} (copies/ug gDNA)	6,419*	47,806	202,543				
Lymphodepletion Regimen	 Fludarabine: 30 mg m²*3 days; Cyclophosphamide: 300 mg m²*3days; ALLO-647 mAb**: 13mg/20mg/30mg*3days 	 Fludarabine: 30 mg m²*3 days; Cyclophosphamide: 300 mg m²*3 days; 	Fludarabine: 25 mg m ² *3 days; Cyclophosphamide: 300 mg m ² *3 days				

*Data from all patients (N=24) receiving the FCA regimen with 3.2 x10⁸ cells.

**ALLO-647: A humanized anti-CD52 monoclonal antibody for the depletion of CD52-positive host lymphocytes.

1. Mailankody, S et al. Nat Med 29, 422–429 (2023)


2. ciltacabtagene autoleucel [Prescribing Information]. Janssen Biotech

3. W Chen, et al. EHA 2024. 2024 May

THANK-uCAR[®] or THANK-u Plus[™]: Innovative Allogeneic CAR-T Platform Aimed to Address Immune Rejection



Target and Hinder the Attack of NK cells on Universal CAR-T cells (THANK-uCAR®)



HvGR is the major challenge faced by Allogeneic CAR-T

• B2M knockout to overcome HvGR from host T cells, but NK cells attack uCAR-T cells without B2M.


THANK-uCAR® to better address HvGR

- Anti-NKG2A CAR protects the uCAR-T cells from NK cell lysis.
- NK cells could act as "feeder cells" for uCAR-T cells, thereby enhancing the expansion of uCAR-T cells.
- NKG2A knockout can further enhance T cell functionality.


Enhanced in Vivo Antitumor Activity of NKG2A-Knocked-Out Allogeneic CAR-T Cells in the Absence of NK Cells

Cells/ul






NKG2A/BCMA triple knock-out: improved efficacy



CD45+ CD45+CD3-


uCAR-T cells survival

NKG2A/BCMA triple knock-out allogeneic CAR-T: enhanced in vivo persistence LAG3/PD-1/TIM3 expression




RPMI-8226 xenograft model

4000



BCMA triple knock-out: improved efficacy

CT0590 Exhibits Enhanced in Vivo Antitumor Activity in Mice in the Presence of NK Cells




ARSGEN

THERAPEUTICS

CT0590 IIT: Study Design



An open-label, single-arm, phase 1, first-in-human trial in China (NCT05066022).



CT0590 IIT: Baseline Characteristics and Outcomes



Patient (Diagnosis)	High risk cytogenetics Y/N	ISS stage	# of prior lines	Refractorine ss to PI/ IMiD*	% Baseline NKG2A expression NK cells	Best overall response	DOR (mo)	TTR (mo)	Peak CAR copy number (copies/µg gDNA)
PT 1 (MM) PT 1-reinf (MM)	Y	I.	2	1	23	SD	NA	NA	BLQ 5,102
PT 2 (MM)	Y	I	2	2	38	sCR	23	1.1	482,749
PT 3 (MM)	Y		3	2	12	SD	NA	NA	BLQ
PT 4 (MM)	Y	111	2		NIA	PR	4	2.3	PL O
PT 4-reinf (MM)	Y	111	3	2	NA	PR	6.9	2.4	BLQ
#PT 5 (pPCL)	Ν	NA	3	2	46	sCR	20	1.2	280,863

This patient was treated under compassionate use

Data cut-off : 22-Apr-2024

* 2 indicates double class refractoriness (to a PI and an IMiD), 1 indicates PT 1 patient refractory to a PI.

- As of April 22, 2024, a total of five patients have been enrolled, 80% of whom exhibited high-risk cytogenetics. Two patients had more than 60% plasma cells in their bone marrow. Both achieved sCR with a DoR of ≥20 months and CAR copy numbers of ≥200,000.
- In the subgroup analysis of the CARTITUDE-1 trial for the autologous BCMA CAR-T cilta-cel, patients with high-risk cytogenetics had an mDoR of 20.1 months, while those with ≥60% plasma cells had an mDoR of 23.1 months.

CT0590: Manageable Safety Profile




	n (%)
SAEs	1 (20.0)
Treatment related TEAEs	4 (80.0)
SAE	0
CRS	2 (40.0)
ICANS	0
GvHD	0
AEs leading to withdrawal	0
AEs leading to death	0
DLT	0

- Two patients experienced CRS
 - ✓ One patient each at Grade 1 and Grade 2; no ≥ Grade 3 CRS;
 - Time to onset was 8-10 days postinfusion;
 - \checkmark Duration was 3-4 days.
- No cases of ICANS or GvHD were observed.
- No DLTs, no withdrawals due to AE, no deaths due to AE

1. Fu C, et al. 2024 ASH. 2024 Dec; Poster 4843

CT0590: Deep and Durable Responses



- 3 subjects achieved confirmed responses including 2 subjects with stringent complete response (sCR) and 1 subject with partial
 response (PR). Patient 1 achieved PR but it could not be confirmed due to COVID-19.
- CAR copies could be detected in 3 out of the 5 patients:
 - Patient 2 remained in remission at the time of data cut-off (Duration of Response [DOR]> 23months); achieved substantial peaks CAR copy numbers of 482,749 copies/µg gDNA at 19 days;
 - Patient 5 with pPCL achieved sCR and was in remission for 20months; achieved substantial peaks CAR copy numbers of 280,863 copies/µg gDNA at 15 days;
 - ✓ Both Patients with sCR presented with \ge 80% bone marrow plasma cells at baseline;
 - No CAR copies were detected in any subject after Week 8.

A Case of CT0590 to Treat R/R MM

Baseline Characteristics

- A 71-year-old male diagnosed with MM,
- Double-refractory, with 94.5% plasma cells in bone marrow.

Safety

- 2 prior lines of therapies, including 3 regimens.
- Received 3×10⁸ CT0590 CAR-T cells infusion.


• 1 Grade CRS

- Only 1 subject had Grade 3 treatment-related infection (pneumonia) on Day 12, which fully resolved.
- No ICANS

Efficacy

 W12: achieved sCR, with a DoR of ≥23 months (ongoing)





A Case of CT0590 to Treat R/R pPCL



Baseline Characteristics


- A 52-year-old male diagnosed with pPCL
- Double-refractory
- 3 prior lines, including 3 regimens (ASCT, etc.)
- Received an infusion of 3×10⁸ CT0590 CAR-T cells.

Safety

- 1 Grade CRS
- Grade 1 infection (pneumonia), unrelated to treatment.
- No ICANS

Efficacy

- sCR with a DoR of 20 months.
- The DoR is more than double the duration reported for autologous BCMA CAR-T treatments in PCL.



Best response	Duration of response	References
1 VGPR	117days (PFS)	Li, C, et al. Clin Transl Med. 2021;11(3):e346.
1 CR	307 days (PFS)	Li, C, et al. Clin Transl Med. 2021;11(3):e346.
1 sCR	7months (DoR)	Deng J, et al. Front Oncol. 2022; 12: 901266.

Previous reports of autologous BCMA CAR-T therapy for multiple myeloma show that the DoR is less than 10 months.

Baseline NKG2A Expression on NK cells may be Predictive of CT0590 Responses




- 4 patients had baseline NKG2A data available.
- Both patients who attained sCR, Patient 2 and Patient 5, had relatively higher NKG2A expression levels on NK cells at 38% and 46% respectively.
- A relatively weak expansion of CT0590 CAR-T cells in vitro in the presence of NK cells with lower NKG2A expression was observed (data not shown here).
- Baseline NKG2A expression levels on NK cells may predict treatment outcomes with CT0590.

Patient (Diagnosis)	Dose (cells)	% Baseline NKG2A expression NK cells	Best overall response
PT 1 (MM)	50×10 ⁶	23	SD
PT 1-reinf (MM)	300×10 ⁶	23	
PT 2 (MM)	300×10 ⁶	38	sCR
PT 3 (MM)	300×10 ⁶	12	SD
PT 4 (MM)	450×10 ⁶	NIA	PR
PT 4-reinf (MM)	450×10 ⁶	NA	PR
PT 5 (pPCL)	300×10 ⁶	46	sCR

1. Fu C, et al. 2024 ASH. 2024 Dec; Poster 4843


THANK-u Plus[™]: Enhanced and Sustained Allogeneic CAR-T Expansion Across Different NKG2A Expression Levels





- THANK-uCAR CT0590 exhibits a decrease in expansion within 72 hours in NK cells with relatively low NKG2A expression, while the expansion of CT059X, produced using THANK-u Plus[™], continues to increase over time.
- CT059X expanded significantly better than CT0590 in the presence of NK cells with medium or high levels of NKG2A expression.

THANK-u Plus[™] Demonstrates Enhanced Anti-Tumor Efficacy in vivo




CT059 X demonstrates significantly greater efficacy than allogeneic CT053 and CT0590, in the presence or absence of NK cells.

Note: uUTD refers to untransduced allogeneic T cells.

Proprietary Allogeneic CD19/CD20 CAR-T Demonstrates Potential Best-in-class Efficacy in Lymphoma Models






CARsgen's allogeneic CD19/CD20 dual-target CAR-T demonstrates superior efficacy in a B-cell lymphoma model, over CD19 or CD20 single-target CAR-Ts, and benchmark CD19/CD20 dual-target CAR-T.

CD19/20X Allogeneic CAR-T Exhibits Robust Anti-lymphoma Activity in the Presence of NK Cells






In the presence of NK cells, CD19/20X allogeneic CAR-T (THANK-u Plus[™] platform) demonstrates much better anti-tumor efficacy than conventional allogeneic CD19/20 CAR-T.


The Sustained and Enhanced Expansion of KJ-C2320 in the Presence of NK Cells from Different Donor Sources





KJ-C2320 Exhibits Enhanced Antitumor Activity in Mice in the Presence of NK Cells





CARSGEN THERAPEUTICS Confidential Copyrights reserved by CARsgen

Summary of CARsgen's Allogeneic CAR-T Platform



- The allogeneic CAR-T therapies targeting BCMA, CD19/CD20, and CD38 currently under development have demonstrated potent anti-tumor efficacy in mouse models, particularly in the presence of NK cells.
- Several allogeneic CAR-T products are currently in development:
 - □ CT0590 targeting BCMA, for R/R MM and R/R PCL (enrollment finished).
 - CT059X targeting BCMA, for R/R MM and R/R PCL, an IIT initiated. The first subject has achieved sCR, following infusion of CAR-T cells at the lowest dose level according to the clinical protocol.
 - KJ-C2219 targeting CD19/CD20, for B-cell malignancies, an IIT initiated; for systemic lupus erythematosus and systemic sclerosis, an IIT initiated.
 - □ KJ-C2320 targeting CD38, for AML, an IIT initiated.
 - □ KJ-C2114 for solid tumors.
 - □ KJ-C2526 targeting NKG2DL, for AML, other malignancies, senescence.
- On February 25, 2025, CARsgen Therapeutics introduced Zhuhai SB Xinchuang to accelerate allogeneic CAR-T cell products development in mainland China.

Multiple Value Inflection Milestones in the Near Future



- **H1 2025**: Planned NDA submission for CT041 to the NMPA.
- **2025 ASCO**: Expected disclosure of CT041 China Phase II pivotal trial data in 3L gastric cancer.
- H2 2025: Anticipated data release for CT041 in pancreatic cancer adjuvant therapy.
- Multiple allogeneic CAR-T products are advancing through development, with upcoming data updates:
 - □ CT059X for R/R MM and R/R PCL;
 - KJ-C2219 for B-cell malignancies and autoimmune diseases;
 - □ KJ-C2320 for AML;
 - □ KJ-C2114 for solid tumors;
 - □ KJ-C2526 for AML, other malignancies, and senescence.

Experienced Senior Management Team









Huamao Wang, PhD Co-founder and COO 上海锐劲生物技术有限公司



Hua Jiang, MD, PhD Vice President, Early Discovery

> 上海市肿瘤研究所 SHANGHAI CANCER INSTITUTE



CARSGEN THERAPEUTICS Confidential Copyrights reserved by CARsgen

Making Cancer Curable

CARSEE

